Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer (PIKNIC)
|ClinicalTrials.gov Identifier: NCT02506556|
Recruitment Status : Unknown
Verified July 2015 by Peter MacCallum Cancer Centre, Australia.
Recruitment status was: Recruiting
First Posted : July 23, 2015
Last Update Posted : July 23, 2015
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Breast Cancer||Drug: BYl719||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||34 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor, in Adult Patients With Advanced Breast Cancer Progressing After First Line Therapy.|
|Study Start Date :||July 2015|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2018|
BYL719 350 mg orally daily until progression, undue adverse events or withdrawal of consent.
Treatment: BYL719 350mg orally daily Treatment will be given daily until progression, undue adverse events or withdrawal of consent.
Dose reductions (two levels) are allowed. Each cycle is 28 days
- Objective response rate [ Time Frame: > 6 months ]The percentage of patients who achieve a complete or partial response as defined by RECIST 1.1 criteria.
- Clinical Benefit Rate [ Time Frame: > 6 months ]Defined as Complete or partial responses according to RECIST 1.1 criteria or stable disease for 6 months or greater
- Progression free survival [ Time Frame: > 6 months ]Defined as the time from study entry until documented disease progression
- Safety and tolerability [ Time Frame: > 6 months ]Safety and tolerability will be described using frequency of significant treatment related adverse events (AEs) using CTCAE 4.0 grade ≥3, all Serious Adverse Events and SUSARs. Safety analysis will include all patients who have received at least one dose of the drug and will be evaluated descriptively
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02506556
|Contact: MedOnc1 Clinical Trials Unit||+61396561111 (ask for CTU)||email@example.com|
|Contact: Terese Masters||+61396561111 ext firstname.lastname@example.org;|
|Study Chair:||Sherene Loi, MD,PhD||Peter MacCallum Cancer Centre, East Melbourne, Victoria, AUSTRALIA|